Buijs W C, Oyen W J, Dams E T, Boerman O C, Siegel J A, Claessens R A, van der Meer J W, Corstens F H
Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands.
Nucl Med Commun. 1998 Aug;19(8):743-51. doi: 10.1097/00006231-199808000-00004.
This study presents data on the dynamic distribution and dosimetry of 111In- and 99Tcm-labelled human non-specific immunoglobulin G (IgG), two recently developed radiopharmaceuticals for the detection of infection and inflammation. Five healthy volunteers were injected with 20-75 MBq 111In-IgG and seven patients were injected with 740 MBq 99Tcm-hydrazinonicotinamide derivative (HYNIC)-IgG. Blood samples, urine and feces were collected. Whole-body gamma camera imaging studies were performed. The activity in source organs was quantified using the conjugate view counting method and a partial background subtraction technique. Dosimetric calculations were performed using the MIRD technique. For 111In-IgG, the mean biological half-times in the blood were 0.90 and 46 h for the a- and b-phase, respectively. For 99Tcm-HYNIC-IgG, these half times were 0.46 and 45 h. For 111In-IgG, the mean cumulative urinary excretion in the first 48 h was 18% of the injected dose, while excretion in the feces was less than 2% of the injected dose. For 99Tcm-HYNIC-IgG, the whole-body retention was always 100% up to 24 h. The mean absorbed doses in the liver, spleen, kidneys, red marrow and testes from 111In-IgG were 0.8, 0.7, 1.2, 0.3 and 0.4 mGy MBq-1 respectively. The mean absorbed doses for 99Tcm-HYNIC-IgG to these organs were 16, 24, 15, 10 and 22 mu Gy MBq-1 respectively. The mean effective dose was 0.25 mSv MBq-1 and 8.4 mu Sv MBq-1 for 111In-IgG and 99Tcm-HYNIC-IgG respectively. In conclusion, the radiation absorbed doses for both 111In-IgG and 99Tcm-HYNIC-IgG are low and, therefore, these radiopharmaceuticals can be administered safely from a radiation risk perspective.
本研究展示了有关111铟和99锝标记的人非特异性免疫球蛋白G（IgG）的动态分布和剂量测定的数据，这两种是最近开发的用于检测感染和炎症的放射性药物。5名健康志愿者注射了20 - 75兆贝克勒尔的111铟 - IgG，7名患者注射了740兆贝克勒尔的99锝 - 肼基烟酰胺衍生物（HYNIC）-IgG。采集了血样、尿液和粪便。进行了全身γ相机成像研究。使用共轭视图计数法和部分背景扣除技术对源器官中的活度进行了定量。使用MIRD技术进行了剂量测定计算。对于111铟 - IgG，α相和β相在血液中的平均生物半衰期分别为0.90小时和46小时。对于99锝 - HYNIC - IgG，这些半衰期分别为0.46小时和45小时。对于111铟 - IgG，前48小时的平均累积尿排泄量为注射剂量的18%，而粪便中的排泄量小于注射剂量的2%。对于99锝 - HYNIC - IgG，直至24小时全身滞留率始终为100%。111铟 - IgG在肝脏、脾脏、肾脏、红骨髓和睾丸中的平均吸收剂量分别为0.8、0.7、1.2、0.3和0.4毫戈瑞/兆贝克勒尔。99锝 - HYNIC - IgG对这些器官的平均吸收剂量分别为16、24、15、10和22微戈瑞/兆贝克勒尔。111铟 - IgG和99锝 - HYNIC - IgG的平均有效剂量分别为0.25毫希沃特/兆贝克勒尔和8.4微希沃特/兆贝克勒尔。总之，111铟 - IgG和99锝 - HYNIC - IgG的辐射吸收剂量都很低，因此，从辐射风险角度来看，可以安全地给予这些放射性药物。
